Literature DB >> 16824608

Salvage treatment of histoplasmosis with posaconazole.

Angela Restrepo1, Angela Tobón, Benjamin Clark, Donald R Graham, Gavin Corcoran, Robert W Bradsher, Mitchell Goldman, George Pankey, Thomas Moore, Ricardo Negroni, John R Graybill.   

Abstract

Six patients received salvage treatment with posaconazole oral suspension (800 mg/day in divided doses) for severe forms of histoplasmosis. One patient had pulmonary disease and 5 had disseminated disease. Previous antifungal therapy consisted of amphotericin B, itraconazole, fluconazole, or voriconazole. Posaconazole treatment duration for individual patients ranged from 6 weeks to 34 weeks. All patients had successful clinical outcomes with significant clinical improvements noted during the first month of therapy. Although the number of patients evaluated in this case series is small, the findings are encouraging and provide preliminary evidence that posaconazole may be a useful salvage treatment option for histoplasmosis involving a variety of infected tissues and organs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16824608     DOI: 10.1016/j.jinf.2006.05.006

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  24 in total

Review 1.  Histoplasmosis: a clinical and laboratory update.

Authors:  Carol A Kauffman
Journal:  Clin Microbiol Rev       Date:  2007-01       Impact factor: 26.132

Review 2.  Transmission of tropical and geographically restricted infections during solid-organ transplantation.

Authors:  P Martín-Dávila; J Fortún; R López-Vélez; F Norman; M Montes de Oca; P Zamarrón; M I González; A Moreno; T Pumarola; G Garrido; A Candela; S Moreno
Journal:  Clin Microbiol Rev       Date:  2008-01       Impact factor: 26.132

Review 3.  Antifungal clinical trials and guidelines: what we know and do not know.

Authors:  Peter G Pappas
Journal:  Cold Spring Harb Perspect Med       Date:  2014-11-03       Impact factor: 6.915

4.  Fusarium peritonitis successfully managed with posaconazole and catheter removal.

Authors:  Punit J Shah; Scott Bergman; Srivalli Vegi; Vidya Sundareshan
Journal:  Perit Dial Int       Date:  2014 Jul-Aug       Impact factor: 1.756

5.  Bats, fever and adenopathy - what is the link?

Authors:  Joshua J Manolakos; Mohan Cooray; Ameen Patel; Shariq Haider
Journal:  Can J Infect Dis Med Microbiol       Date:  2013       Impact factor: 2.471

6.  Head and neck histoplasmosis--a nightmare for clinicians and pathologists! Experience at a tertiary referral cancer centre.

Authors:  Seethalakshmi Viswanathan; Naveen Chawla; Anil D'Cruz; Shubhada V Kane
Journal:  Head Neck Pathol       Date:  2007-11-27

Review 7.  Pharmacologic and clinical evaluation of posaconazole.

Authors:  Jason N Moore; Jason R Healy; Walter K Kraft
Journal:  Expert Rev Clin Pharmacol       Date:  2015-05       Impact factor: 5.045

Review 8.  Dimorphic fungal osteoarticular infections.

Authors:  B Rammaert; M N Gamaletsou; V Zeller; C Elie; R Prinapori; S J Taj-Aldeen; E Roilides; D P Kontoyiannis; B Brause; N V Sipsas; T J Walsh; O Lortholary
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-06-18       Impact factor: 3.267

Review 9.  Endemic Mycoses in Solid Organ Transplant Recipients.

Authors:  Jeremy S Nel; Luther A Bartelt; David van Duin; Anne M Lachiewicz
Journal:  Infect Dis Clin North Am       Date:  2018-09       Impact factor: 5.982

Review 10.  Development, clinical utility, and place in therapy of posaconazole for prevention and treatment of invasive fungal infections.

Authors:  Emily Zoller; Connie Valente; Kyle Baker; Michael E Klepser
Journal:  Drug Des Devel Ther       Date:  2010-11-04       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.